Sanofi to shutter 370-worker plant in KC

Sanofi-Aventis is exchanging the "For Sale" sign on its Kansas City plant for another that says, "Closed." After scouting for a buyer for more than a year, the drugmaker is shutting down the facility, which employs 370 people. Workers were told during a site meeting late last week.

Apparently, the drugs made in Kansas City weren't growing fast enough for Sanofi. "There were a number of criteria involved in deciding to close, but ultimately, it was a lack of growth in demand for the products," Jack Cox, a Sanofi spokesman, told the Kansas City Star.  A few potential buyers kicked around the plant, but ultimately the proposals Sanofi got "weren't sufficient to sustain the facility," Cox said.

The phased shutdown will wrap up by mid-2012, and employees will get a transition bonus and assistance in finding new work. "Our priority will be to help employees ... while gradually reducing our manufacturing levels," site leader Osric Kirk Reavis said in a statement. More details to come by the end of November.

- read the Sanofi release
- see the KC Star article

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.